In Depth 27 Feb 2024
Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?
Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition.
In Depth
- Latest Posts
In Depth 22 Feb 2024
TIL therapies: the impact on cancer research
The approval of the first-ever TIL therapy has made it possible to treat hundreds of thousands of people affected by skin cancer in the US.
In Depth 21 Feb 2024
Cytokine release syndrome: how pharma is tackling a 21st century disease
Explore the frontier of biotech’s battle against cytokine release syndrome (CRS), from historical setbacks to cutting-edge solutions.
In Depth 15 Feb 2024
Turning the tide: recent advancements in childhood cancer research
As we observe International Childhood Cancer Day today, let us take a look at some of the recent advancements in childhood cancer research.
In Depth 15 Feb 2024
Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug?
Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment.
In Depth 14 Feb 2024
The next leap in pet health: longevity drugs for dogs
Find out how we could stave off the heartbreak of saying goodbye to our dogs, as three longevity drugs for dogs could soon be approved.
ADVERTISEMENT
ADVERTISEMENT
In Depth 12 Feb 2024
RNA editing set to take off: could DNA’s short-lived cousin overcome the limitations of CRISPR gene editing?
Find out all about about RNA editing, as two candidates have just managed to reach the clinic for the first time.
In Depth 9 Feb 2024
Biotech job market 2024: what to expect?
The past year saw pipeline cuts and downsizing plans strike the biotech industry. Does the biotech job market seem to be looking up this year?
In Depth 8 Feb 2024
Could we see a new dawn for hair loss treatments?
Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors.
In Depth 7 Feb 2024
The biggest private biotech investments in January 2024
Jixing Pharmaceuticals, COUR Pharmaceuticals, and OnCusp Therapeutics bagged the biggest private biotech investments in January 2024.
In Depth 5 Feb 2024
Future of cancer treatment: what will therapy look like in 2034?
From groundbreaking immunotherapies to AI diagnostics and new vaccines, explore the innovations shaping the future of cancer treatment.
In Depth 31 Jan 2024
New epilepsy drugs: what is in the pipeline?
Find out about the new epilepsy drugs currently in the pipeline, as resistance to current AEDs underscores the need for new treatments.
ADVERTISEMENT
